On such low volume, they can have their way with this stock. The bottom line may be market cap vs. growth prospects. Contrast a ridiculously small market cap of ~$16m vs. blockbuster products selling in over 400 (and counting) collectives and dispensaries throughout CA, in situ and online. Not even considering the likelihood of out-of-state dispensary sales and the possibility, down the road, of entry of non-psychoactive Dharmanol™ line into regular retail venues nationwide. SKTO's Allyn: "Our goal is to be nationwide."